AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...

CagriSema is a once-weekly injection combining cagrilintide and semaglutide, the active ingredient in Novo Nordisk's successful drug Wegovy. The drugmaker expects to file for its first regulatory ...

The drug, a mix of cagrilintide and semaglutide, a key ingredient in the company's current blockbuster drugs Ozempic and Wegovy, is being tested for obesity and Type 2 diabetes as a once-weekly ...

Cagrilintide is currently being developed in combination with semaglutide to see if it helps overweight and obese people achieve sustained weight loss. Novo said it will detail results from both ...

REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.

The stock was trading down more than 5.5% at the time of writing following the revelation that in the REDEFINE 2 trial, CagriSema (cagrilintide and semaglutide) achieved a weight loss of 15.7% ...

CagriSema combines semaglutide, the main ingredient in Wegovy, with cagrilintide, another engineered peptide. Cagrilintide, a long-acting version of the hormone amylin, activates the amylin ...

REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 68 weeks, 89.7% of adults with obesity and type 2 ...

CagriSema is a two-drug combination that mixes its blockbuster Semaglutide drug found in Ozempic and Wegovy, with a experimental drug cagrilintide. An earlier study of the drug late last year ...